Why NHC Stock dropped -2.84% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, NHC scores 73 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars break down as follows:

• Fundamental Cash Engine: 16 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 10.1% and an FCF yield of 4.47%. For a prospective investor, this indicates the business generates returns above the level the rating treats as a baseline and converts a meaningful share of market value into free cash flow.
• Whale 13F Flow: 9 / 20. The lowest pillar. Per the Roarable RQD rating, it covers institutional accumulation and options positioning. The modest score suggests institutional conviction is not a strong tailwind; the source data does not provide the underlying 13F or options detail behind this score.
• Insider Conviction: 15 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The score is moderately positive, but the source data does not itemize the trades.
• Macro Regime Fit: 15 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. A beta of 1.0 implies the stock is expected to move roughly in line with the broad market, so macro exposure is neutral-to-average rather than amplified.
• Forensic Balance Sheet: 18 / 20. The strongest pillar. Per the Roarable RQD rating, Altman Z is 6.61, Piotroski F is 8/9, and Debt/Equity is 0.03. These figures point to very low leverage and strong financial health, which reduces downside risk from solvency concerns.

Investor implications. The upside case rests on the cash engine and balance sheet: strong returns, healthy cash conversion, and minimal debt give management room to operate or reinvest. The valuation tradeoff is that per the market data, P/E (TTM) is 27.7 versus a forward P/E of 23.3, and EV/EBITDA is 20.5; the stock is not cheap on trailing earnings, so the thesis depends on earnings growth delivering the implied improvement. The weakest input is institutional flow (9 / 20), which suggests the rating's positive verdict leans primarily on fundamentals rather than broad professional conviction. Price sits at 212.16 within a 52-week range of $118.14 – $248.2, placing it closer to the upper portion of that range.

National HealthCare Corporation (NHC) is a NYSE-listed issuer in the Health Care sector, within the Hospital/Nursing Management industry, per the profile. The profile describes it as a Health Care issuer operating in that industry with a market capitalization of $3.3B. Per the market data, gross margin is reported as 0%, operating margin is 8.5%, and net margin is 7.9%. Not available in source data: specific products, customer segments, or revenue model descriptions.

Per the SEC financials, revenue grew from $1141.5M (FY 2023) to $1517.8M (FY 2025), and operating income rose from $57.5M to $128.4M over the same span. Net income was $120.0M in FY 2025 against $101.9M in FY 2024. Per the Roarable RQD rating, ROIC is 10.1%, Altman Z-Score is 6.61, and Piotroski F-Score is 8/9. Debt declined from $129.5M (FY 2024) to $32.5M (FY 2025), and the Debt/Equity ratio is reported at 0.03.

Per the recent news data, six items were reported, with light signals as follows:

• Market Wire (YELLOW): Yahoo Finance stock forecast coverage; Seeking Alpha coverage citing improving business metrics and future operating leverage; MarketBeat stock coverage; a Stock Titan item on three entities reporting NHC shares while disclaiming beneficial ownership; a MarketBeat item noting the stock breaking above its 200-day moving average.
• Risk Watch (RED): AlphaStreet reported NHC dropped 5.2% amid sector-wide selling.

The news data does not provide full article text, so the substance behind the headlines is limited to the headlines and summaries provided. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links. Not available in source data: upstream suppliers, downstream customers, or sector-correlation relationships. The sector assignment (Health Care) and industry (Hospital/Nursing Management) are the only structural context provided. A prospective investor should watch sector-wide selling, referenced in the AlphaStreet item, as a potential ripple, but the source data does not specify the transmission mechanism.

Not available in source data for analyst consensus, price targets, and holder data: the analyst data and holders sections are recorded as NONE. Per the Roarable RQD rating, the Whale 13F Flow pillar scores 9 / 20 and the Insider Conviction pillar scores 15 / 20; the underlying trade-level detail is not provided.

• What drove the gross margin figure of 0% versus the reported operating and net margins, and is that a data-classification artifact?
• What are the EPS figures for FY 2023 through FY 2025, which are reported as N/A in the financials?
• What is the FY 2023 cash and debt position, which is reported as N/A?
• Which specific institutional holders and insider transactions make up the 9/20 whale and 15/20 insider pillar scores?
• What is the operating-leverage thesis referenced in the Seeking Alpha headline, and what metrics support it?